- Home
- PEBK vs IPHA Comparison
PEBK vs IPHA Comparison
Compare PEBK & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEBK
- IPHA
- Stock Information
- Founded
- PEBK 1912
- IPHA 1999
- Country
- PEBK United States
- IPHA France
- Employees
- PEBK N/A
- IPHA N/A
- Industry
- PEBK Major Banks
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- PEBK Finance
- IPHA Health Care
- Exchange
- PEBK Nasdaq
- IPHA Nasdaq
- Market Cap
- PEBK 162.7M
- IPHA 160.1M
- IPO Year
- PEBK N/A
- IPHA 2019
- Fundamental
- Price
- PEBK $29.43
- IPHA $1.97
- Analyst Decision
- PEBK
- IPHA Strong Buy
- Analyst Count
- PEBK 0
- IPHA 3
- Target Price
- PEBK N/A
- IPHA $5.00
- AVG Volume (30 Days)
- PEBK 6.1K
- IPHA 24.2K
- Earning Date
- PEBK 10-20-2025
- IPHA 09-17-2025
- Dividend Yield
- PEBK 3.25%
- IPHA N/A
- EPS Growth
- PEBK 3.81
- IPHA N/A
- EPS
- PEBK 3.06
- IPHA N/A
- Revenue
- PEBK $85,500,000.00
- IPHA $14,839,695.00
- Revenue This Year
- PEBK N/A
- IPHA $50.89
- Revenue Next Year
- PEBK N/A
- IPHA N/A
- P/E Ratio
- PEBK $9.62
- IPHA N/A
- Revenue Growth
- PEBK 6.88
- IPHA N/A
- 52 Week Low
- PEBK $23.74
- IPHA $1.29
- 52 Week High
- PEBK $33.90
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- PEBK 43.40
- IPHA 44.78
- Support Level
- PEBK $29.12
- IPHA $1.95
- Resistance Level
- PEBK $31.95
- IPHA $2.40
- Average True Range (ATR)
- PEBK 0.80
- IPHA 0.12
- MACD
- PEBK -0.09
- IPHA -0.01
- Stochastic Oscillator
- PEBK 29.36
- IPHA 4.44
About PEBK Peoples Bancorp of North Carolina Inc.
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.